Authors' Reply

Affiliations

¹ Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, New York.
² Keck School of Medicine, University of Southern California, Los Angeles, California.
³ Pham Ngoc Thach, University of Medicine, Ho Chi Minh City, Vietnam.
⁴ Global Medicines Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.

Comment

Steven Fishbane et al. J Am Soc Nephrol. 2021.

. 2021 Jun 1;32(6):1537-1538.

doi: 10.1681/ASN.2021030334. Epub 2021 Apr 13.

¹ Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, New York.
² Keck School of Medicine, University of Southern California, Los Angeles, California.
³ Pham Ngoc Thach, University of Medicine, Ho Chi Minh City, Vietnam.
⁴ Global Medicines Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.

No abstract available

Keywords: anemia; chronic kidney disease; erythropoietin.

Comment on

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE. Fishbane S, et al. J Am Soc Nephrol. 2021 Mar;32(3):737-755. doi: 10.1681/ASN.2020081150. Epub 2021 Feb 10. J Am Soc Nephrol. 2021. PMID: 33568383 Free PMC article. Clinical Trial.
On the Increased Event Rate of Urinary Tract Infection and Pneumonia in CKD Patients Treated with Roxadustat for Anemia.
Eleftheriadis T, Pissas G, Liakopoulos V, Stefanidis I. Eleftheriadis T, et al. J Am Soc Nephrol. 2021 Jun 1;32(6):1537. doi: 10.1681/ASN.2021020204. Epub 2021 Apr 13. J Am Soc Nephrol. 2021. PMID: 33849917 Free PMC article. No abstract available.

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease.
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. Cochrane Database Syst Rev. 2022. PMID: 36005278 Free PMC article.
Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat.
Czock D, Keller F. Czock D, et al. Clin Pharmacokinet. 2022 Mar;61(3):347-362. doi: 10.1007/s40262-021-01095-x. Epub 2021 Dec 14. Clin Pharmacokinet. 2022. PMID: 34905154 Free PMC article. Review.

1. Eleftheriadis T, Pissas G, Liakopoulos V, Stefanidis I: On the increased event rate of urinary tract infection and pneumonia in chronic kidney disease patients treated with roxadustat for anemia. J Am Soc Nephrol 32: 1537, 2021. - PMC - PubMed
1. Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, et al. .: Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized Phase 3 study. J Am Soc Nephrol 32: 737–755, 2021. - PMC - PubMed
1. Eleftheriadis T, Pissas G, Mavropoulos A, Nikolaou E, Filippidis G, Liakopoulos V, et al. .: In mixed lymphocyte reaction, the hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat suppresses cellular and humoral alloimmunity. Arch Immunol Ther Exp (Warsz) 68: 31, 2020. - PubMed
1. Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, et al. .: Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for treatment of anemia in chronic kidney disease: A placebo-controlled study of pharmacokinetic and pharmacodynamic profiles in hemodialysis patients. J Clin Pharmacol 60: 1432–1440, 2020. - PMC - PubMed
1. Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, et al. .: Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A Phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67: 912–924, 2016. - PubMed